Drugs that contain Brexpiprazole
1. Drug name - REXULTI
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7888362 | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Apr, 2026
(3 years from now) | |
| USRE48059 | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Dec, 2028
(6 years from now) | |
| CN101155804A | OTSUKA | Piperazine-Substituted Benzothiophenes For Treatment Of Mental Disorders |
Apr, 2026
(3 years from now) | |
| CN101155804B | OTSUKA | For Treating Mental Disease Piperazine Substituted Benzothiophene |
Apr, 2026
(3 years from now) | |
| IN251204B | OTSUKA | A Heterocyclic Compound Represented By The Formula(1) |
Apr, 2026
(3 years from now) | |
| IN200707041P1 | OTSUKA | Piperazine-Substituted Benzothiophenes For Treatment Of Mental Disorders |
Apr, 2026
(3 years from now) | |
| EP1869025B3 | OTSUKA | Piperazine-Substituted Benzothiophenes For Treatment Of Mental Disorders |
Apr, 2026
(3 years from now) | |
| EP1869025A1 | OTSUKA | Piperazine-Substituted Benzothiophenes For Treatment Of Mental Disorders |
Apr, 2026
(3 years from now) | |
| EP1869025B1 | OTSUKA | Piperazine-Substituted Benzothiophenes For Treatment Of Mental Disorders |
Apr, 2026
(3 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8618109 | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Apr, 2026
(3 years from now) | |
| US8349840 | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Apr, 2026
(3 years from now) | |
| US9839637 | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Apr, 2026
(3 years from now) | |
| US10307419 | OTSUKA | Tablet comprising 7-[4-(4-benzo[b]thiopen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof |
Oct, 2032
(10 years from now) | |
Treatment: Treatment of schizophrenia; treatment of schizophrenia in adults and pediatric patients ages 13 years and older; Adjunctive treatment of major depressive disorder (mdd); Adjunctive treatment of major depressive disorder (mdd); treatment of schizophrenia; treatment of schizophrenia in adults and pediatric patients ages 13 years and older
Dosage: TABLET;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 0.25MG | TABLET;ORAL | Prescription |
| 0.5MG | TABLET;ORAL | Prescription |
| 1MG | TABLET;ORAL | Prescription |
| 2MG | TABLET;ORAL | Prescription |
| 3MG | TABLET;ORAL | Prescription |
| 4MG | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.